andi roy
@andiroy
Followers
1K
Following
6K
Media
238
Statuses
2K
Clinician Scientist and Professor of Paediatric Haematology at University of Oxford. Developmental haematopoiesis and leukaemia
Joined March 2009
Very excited about this paper! This was a wonderful collaborative project with Karadimitris lab @ImperialImmuno . Thanks to funders @CRUKresearch and @CwC_UK_Research . On #CCAM , we hope this brings us closer to curing #InfantALL
ox.ac.uk
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for
6
5
26
So proud of Rebecca for getting this @CRISCANCERUK fellowship to continue her clinical academic career! These intermediate fellowships are so valuable for clinician scientists 🎉@MRC_MHU @OxPaediatrics @OxfordCancer
cancer.ox.ac.uk
Oxford Cancer, together with the CRIS Cancer Foundation, is delighted to announce the appointment of the 2025 CRIS Cancer Postdoctoral Clinical Fellows: Dr Rebecca Ling and Dr Casmir Turnquist. Both...
0
1
6
Read about our latest research funded by @CRUKresearch and @CwC_UK_Research @CwC_UK . Thanks for this news item to close #CCAM. @OxPaediatrics @MRC_MHU @MRC_WIMM @ImperialImmuno
news.cancerresearchuk.org
iNKT cell therapy could make it possible to stop hard-to-treat forms of leukaemia using donated immune cells.
0
2
10
Join me in The Science of Childhood Cancer lecture series hosted by @StJudeResearch this Thursday, September 25 at 12 CT/1pm ET where I will be presenting Developmental origins of infant acute lymphoblastic leukaemia. Register to attend: https://t.co/hX9wcSR5s8
1
4
10
Read about our @cclguk @LPTrustUK funded research published @BloodPortfolio @BloodAdvances . Well done to 1st author @J_W_Cross and @cyeld who started the project off. Many thanks to @milnetom68 and other collaborators. https://t.co/S9iVmnD7Cj
1
6
20
A short clip where we discuss our hopes for children with high risk ALL. Thanks @KaiyaFoundation for supporting our research and @TTVOxfordshire for highlighting this during #CCAM @OxPaediatrics @MRC_MHU @MRC_WIMM
Professor Anindita Roy from the Childhood Leukaemia Research Group told That's TV about what she hopes they can achieve with new funding from the Kaiya's Foundation. Annu Patel, Kaiya's mum, told That's TV the foundation's continued work allows her daughter's memory to live on
0
3
17
Had a wonderful time as always at @CLRUKnetwork annual meeting. It was great fun organising it with @LJRussell_Lab @Keeshanlab and @Bill_G_Grey . Very proud of Lucy Hamer for an excellent talk! #CCAM #bloodcancerawarenessmonth
0
1
8
Well done Dr Emily Neil from our group @OxPaediatrics @MRC_MHU @MRC_WIMM on this award from the Kaiya Foundation to study VHR childhood ALL. #CCAM #bloodcancerawareness month.
"Over the next year the plan is to look more specifically at the molecular mechanisms that occur during the initiation of the leukaemia." That's TV spoke to Dr Emily Neil about the grant she has been awarded for her research into leukaemia.
0
0
6
HMN 2025: How New, ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukemia
0
0
1
New in @BloodPortfolio! 🩸 Researchers with Dr. Karadimitris equip iNKT with CD19- and/or CD133-targeting CARs and investigate their anti-#leukemia activity against KMT2A-rearranged acute lymphoblastic leukemia in vivo and in vitro. 🧫 https://t.co/flNZxRwj4p
0
4
19
NEWS: New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia Scientists have found that a modified therapy called CAR-iNKT is highly efficient when compared with standard CAR-T therapy. https://t.co/EUKyxPPdyM
medsci.ox.ac.uk
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for...
1
2
4
Pleased that the 2nd part of my PhD in now available as a preprint! Here, we investigated the epigenomic and transcriptomic changes occurring upon PRC2 depletion in AML cells. https://t.co/xc0v6DUXW3. A thread🧵1/17
biorxiv.org
Background Polycomb Repressive Complex 2 (PRC2) modulates chromatin accessibility and architecture to direct tissue-specific gene expression. PRC2 function is frequently altered in cancer by loss-o...
2
4
12
@ElliottNatalina Also huge thanks to @milnetom68 @halsey_lab and other collaborators: Rachael Bashford-Rogers, Owen Smith, @jbond2019 @DrJackBartram
0
0
2
Link to paper here. Special congratulations to co-first authors Hongwei Ren and @ElliottNatalina .
ashpublications.org
Key Points. ‘Off-the-shelf’ bispecific CD133-CD19 CAR-iNKT cells eradicate CAR antigen-high and -low medullary and leptomeningeal KMT2Ar ALLCAR and CAR-ant
1
1
4
A modified CAR-iNKT therapy that targets two markers (CD19 + CD133) eliminated a high-risk childhood leukaemia in mice, outperforming standard CAR-T therapy. 💉 This is a step toward more efficient treatments for children with leukaemia.❤️🩹 https://t.co/E6WczN4jKq
imperial.ac.uk
CHILD LEUKAEMIA TREATMENT - Scientists found that using two targets in CAR-iNKT therapy in mice can outperform standard treatments for high-risk childhood leukaemia.
1
2
10
A great couple of days at ‘the other place’ 😉. Thanks for the invitation and hospitality Brian Huntly and Cambridge Haematology team. Was good to catch up with collaborators and friends and hear about some great science. #bloodcancerawareness month
0
0
9